Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma

Published:2017 Issue:4 Volume:92 Page:229-242
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Camacho Ximena,Machado Camila Longo,García María Fernanda,Gambini Juan Pablo,Banchero Agustina,Fernández Marcelo,Oddone Natalia,Bertolini Zanatta Daniela,Rosal Carolina,Buchpiguel Carlos Alberto,Chammas Roger,Riva Eloisa,Cabral Pablo

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference36 articles.

1. CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor

2. Anti-CD20-based therapy of B cell lymphoma: state of the art

3. The therapeutic potential of anti-CD20

4. Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

5. Radioimmunotherapy of non-Hodgkin lymphomas

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Imaging of Melanoma VEGF-expressing Tumors through [^99mTc]Tc-HYNIC-Fab(Bevacizumab);Anti-Cancer Agents in Medicinal Chemistry;2024-11

2. Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors;Cancer Biotherapy and Radiopharmaceuticals;2024-06-01

3. Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors;2023-07-18

4. 99mTc-HYNIC/Cy7-Fab(Bevacizumab): su empleo como agente de imagen en mieloma múltiple;Salud Militar;2023-05-29

5. Advances in engineered exosomes towards cancer diagnosis and therapeutics;Progress in Biomedical Engineering;2022-07-01